Quinapril is an ACE inhibitor prodrug used to treat hypertension, congestive heart failure, and slow rate of progression of renal disease. Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.
- Mechanism
- Curator reviewed · 6 references
Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption. This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation. Angiotensin II also stimulates production of plasminogen activator inhibitor-1 (PAI-1), increasing the risk of thrombosis.
Quinaprilat prevents the conversion of angiotensin I to angiotensin II by inhibition of angiotensin converting enzyme, and also reduces the breakdown of bradykinin. Reduced levels of angiotensin II lead to lower levels of PAI-1, reducing the risk of thrombosis, especially after a myocardial infarction.
- Primary indication
- Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure.Curator reviewed · 6 structured indications
- Formula / weight
- C25H30N2O5 · 438.5161 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1991
- Code names
- C09AA06
- Brand names
Resolves to
JSDRRTOADPPCHY-HSQYWUDLSA-NSMILESCCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Quinapril, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account